From Name:
From Email:
To Name:
To Email:

Optional Message:

5. Optimal chemo for ovarian cancer fails to emerge

from MedPage Today

From March 30: A roomful of gynecologic oncologists walked away disappointed after results of a long-awaited ovarian cancer trial failed to show an advantage for any of three chemotherapy regimens. The regimens — involving combinations of intraperitoneal (IP) and intravenous (IV) chemotherapy plus bevacizumab (Avastin) — led to a median progression-free survival (PFS) of 27 to 29 months in patients with optimally debulked stage II-III disease. An analysis limited to patients with optimal stage III disease yielded median PFS values of 31 to 34 months. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063